Oxford BioMedica PLC (OXBDF)

[marcusl2]

Novartis plans additional regulatory submissions for Kymriah in pediatric and young adult patients with r/r B-cell ALL and adult patients with r/r DLBCL beyond the US and EU in 2018
Building on the company's experience, having manufactured CAR-T cells for over 300 patients from 11 countries across various indications in clinical trials,

Active research programs are underway targeting other hematologic malignancies and solid tumors, and include efforts focused on next generation CAR-Ts that involve simplified manufacturing schemes and gene edited cells.

Stephen J. Schuster, MD

Celgene in talks to buy Juno Shares of Juno, which has a market value of $5.57 billion, were up 42 percent at $64.59 in extended trading.